Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioadenosine phosphorylase, or MTAP-deletion urothelial cancer, based on preliminary safety and clinical efficacy data.
The prevalence of MTAP-deletion is estimated at 26% in the cancer type, the company said. An update on the program is planned later this year.
Ideaya said it is the study sponsor, while Gilead will supply Trodelvy.
Ideaya shares were up 4.4% in recent premarket activity, while Gilead rose 1.4%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。